First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
And the company might one day follow Galapagos into decentralised manufacturing.
JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.
In first-line NSCLC the drug beats chemo, and not Keytruda.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
